BMO Capital lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $566 but keeps an Outperform rating on the shares. The company’s Suzetrigine Phase 2 LSR – lumbosacral radiculopathy – data slightly muddied the water for chronic pain, but the firm contends that Vertex can make Phase 3 amendments like a placebo run-in and specific site selection to mitigate placebo effects, bringing response rates more in line with previous trials, the analyst tells investors in a research note. BMO adds that it remains positive on the opportunity for suzetrigine in acute/chronic pain for Vertex Pharmaceuticals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein
- Vertex could be down 10% due to LSR disappointment, says Wells Fargo
- Vertex price target lowered to $535 from $600 at H.C. Wainwright
- Vertex Pharmaceuticals price target lowered to $418 from $509 at Barclays
- Oppenheimer downgrades Vertex after lumbosacral radiculopathy study